Loading...
XSHG600129
Market cap1.60bUSD
Jan 15, Last price  
21.06CNY
1D
-4.19%
1Q
-10.80%
Jan 2017
22.80%
Name

Chongqing Taiji Industry(Group)Co.

Chart & Performance

D1W1MN
XSHG:600129 chart
P/E
14.27
P/S
0.75
EPS
1.48
Div Yield, %
1.13%
Shrs. gr., 5y
0.60%
Rev. gr., 5y
7.88%
Revenues
15.62b
+11.19%
3,879,212,1363,922,489,1434,054,701,0404,407,219,1294,814,879,5905,275,145,7125,985,619,8246,385,801,3546,596,977,5626,603,077,7146,958,053,4807,164,633,0007,788,055,7338,734,522,95710,689,384,28111,643,087,42611,207,803,71112,149,432,71914,050,659,36415,622,648,416
Net income
822m
+131.99%
67,039,88851,198,84947,848,20063,591,64423,501,00137,699,879020,679,704012,559,8220231,980,898853,318,45798,133,50470,263,495032,087,7470354,381,876822,124,918
CFO
672m
-62.71%
172,581,463406,068,087273,533,360240,007,181297,456,589338,274,782124,967,518172,379,99880,079,87000000104,409,864327,246,057749,791,289558,812,7951,800,768,932671,536,615
Dividend
Jun 07, 20240.3 CNY/sh
Earnings
May 16, 2025

Profile

Chongqing Taiji Industry(Group) Co.,Ltd operates in the pharmaceutical industry in China and internationally. It researches, develops, produces, and sells Chinese medicine and health products. The company offers its products in various dosage forms, including tablets, oral liquids, syrups, dripping pills, granules, capsules, tinctures, powders, etc. It offers its products in various areas, such as digestive system, respiratory system, cardiovascular and cerebrovascular, pediatrics and gynecology, systemic anti-infective drugs, analgesia and antibiotics, orthopedics, cold clearing and cough relief, and endocrine and nervous system drugs. The company is based in Chongqing, China.
URL
http://www.taiji.com
IPO date
Nov 18, 1997
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
15,622,648
11.19%
14,050,659
15.65%
Cost of revenue
12,926,064
12,689,204
Unusual Expense (Income)
NOPBT
2,696,584
1,361,455
NOPBT Margin
17.26%
9.69%
Operating Taxes
173,106
103,436
Tax Rate
6.42%
7.60%
NOPAT
2,523,478
1,258,019
Net income
822,125
131.99%
354,382
 
Dividends
(133,031)
Dividend yield
0.51%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
3,284,091
3,928,043
Long-term debt
545,871
737,107
Deferred revenue
139,028
140,869
Other long-term liabilities
657,893
539,215
Net debt
1,453,244
2,053,061
Cash flow
Cash from operating activities
671,537
1,800,769
CAPEX
(835,590)
Cash from investing activities
(627,075)
Cash from financing activities
(363,611)
FCF
2,495,484
890,768
Balance
Cash
2,100,874
2,612,088
Long term investments
275,844
Excess cash
1,595,586
1,909,556
Stockholders' equity
1,567,449
1,060,986
Invested Capital
6,564,114
6,849,899
ROIC
37.62%
18.09%
ROCE
33.10%
17.12%
EV
Common stock shares outstanding
556,891
556,891
Price
46.46
54.56%
30.06
33.84%
Market cap
25,873,144
54.56%
16,740,135
33.84%
EV
27,450,045
18,793,196
EBITDA
3,144,765
1,785,115
EV/EBITDA
8.73
10.53
Interest
151,398
152,708
Interest/NOPBT
5.61%
11.22%